Tumour suppressor genes encode proteins that actively restrain cell proliferation, promote DNA repair, or eliminate damaged cells. Unlike oncogenes, which require only a single activating mutation, tumour suppressors typically require biallelic inactivation (Knudson's two-hit hypothesis) before their protective effect is lost. Three tumour suppressor networks dominate oncogenesis: the p53 network (integrating DNA damage and oncogenic stress signals), the pRb network (controlling the G1/S restriction point), and the PTEN/PI3K network (counteracting survival signalling). These networks are deeply interconnected — p53 regulates MDM2 (which regulates p53 through feedback), PTEN loss activates AKT which degrades p53 through MDM2, and CDKN2A deletion removes the guardians of both pRb and p53 simultaneously.
The three major tumour suppressor networks form an integrated defence system: p53 detects DNA damage and oncogenic stress, imposing arrest or apoptosis via p21 and BAX/PUMA; pRb enforces the G1/S restriction point by sequestering E2F transcription factors; and PTEN opposes survival signalling through PIP3 dephosphorylation. These networks are reinforced by cross-talk: p53 represses BCL2 (pro-survival), activates pRb targets indirectly through p21, and is stabilised by ARF (CDKN2A). Loss of any one network dramatically accelerates loss of the others through relieved selective pressure.
The three major tumour suppressor networks form an integrated defence system: p53 detects DNA damage and oncogenic stress, imposing arrest or apoptosis via p21 and BAX/PUMA; pRb enforces the G1/S restriction point by sequestering E2F transcription factors; and PTEN opposes survival signalling through PIP3 dephosphorylation. These networks are reinforced by cross-talk: p53 represses BCL2 (pro-survival), activates pRb targets indirectly through p21, and is stabilised by ARF (CDKN2A). Loss of any one network dramatically accelerates loss of the others through relieved selective pressure.
PTEN dephosphorylates PIP3→PIP2, opposing PI3K-generated PIP3 and limiting AKT activation. AKT drives survival (BAD phosphorylation), p53 degradation (MDM2 activation), and proliferation (GSK3β inactivation, cyclin D1 stabilisation). PTEN loss therefore simultaneously activates survival, proliferation, and p53 suppression.
The CDKN2A locus encodes p16INK4a (inhibiting CDK4/6 → protecting pRb) and p14ARF (sequestering MDM2 → protecting p53). This dual-gene locus provides coordinated protection of both networks. Homozygous deletion at a single genomic locus disables both tumour suppressor circuits simultaneously — explaining the extraordinary selective advantage and frequency of CDKN2A deletion.
BRCA1 integrates with the p53 network (ATM→BRCA1→HR repair) to ensure DSBs are repaired faithfully before S phase amplifies mutations. BRCA1 loss forces error-prone NHEJ repair, generating structural variants (deletions, translocations) that drive genomic instability and accumulate additional tumour suppressor losses over time.
Tumour suppressor network loss creates synthetic lethal vulnerabilities: BRCA1 loss creates PARP inhibitor sensitivity; PTEN loss creates PI3K inhibitor sensitivity; p53 loss creates ATR/CHK1 inhibitor sensitivity (eliminating the S/G2 checkpoint backup). Identifying which networks are lost in individual tumours guides combination therapy design.
The vast majority of cancers inactivate at least two of these three major tumour suppressor networks, with the specific combination determining cancer subtype, prognosis, and therapeutic vulnerabilities. Li-Fraumeni syndrome (TP53), BRCA syndrome (BRCA1/2), Cowden syndrome (PTEN), and retinoblastoma (RB1) each demonstrate the consequence of heritable network deficiency, with cancer penetrance approaching 100% lifetime risk for some syndromes.
Tumour suppressor restoration therapy remains challenging (TP53 reactivation by APR-246/eprenetapopt, MDM2 inhibitors to restore p53 in wild-type cases). The more tractable approach exploits synthetic lethalities created by network loss: PARP inhibitors for HR-deficient tumours, PI3K inhibitors for PTEN-loss tumours, ATR inhibitors for p53-deficient tumours. Identifying the specific network loss pattern in each patient tumour via comprehensive genomic profiling is the foundation of network-based precision oncology.
Why is it so common to see multiple tumour suppressor losses in the same tumour?
Loss of the first tumour suppressor generates genomic instability that accelerates acquisition of subsequent mutations. For example, TP53 loss prevents apoptosis after DNA damage, allowing cells with additional tumour suppressor mutations to survive. BRCA1 loss generates structural variants that can delete CDKN2A or RB1. Each sequential loss accelerates the accumulation of subsequent losses through elevated mutation rates and reduced apoptotic surveillance.
What is the two-hit hypothesis and does it always apply?
Knudson's two-hit hypothesis states that both alleles of a tumour suppressor gene must be inactivated before its protective effect is lost — one inherited (germline) hit and one somatic hit in hereditary cases, or two independent somatic hits in sporadic cases. It applies to classical recessive tumour suppressors (RB1, TP53, BRCA1, PTEN). However, haploinsufficiency tumour suppressors (some PTEN mutations, NF1) can show effects with only one allele lost, and dominant negative p53 mutations can inactivate remaining wild-type p53 from a single allele.
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
PI3K/AKT/mTOR Signalling Pathway
The PI3K/AKT/mTOR pathway is the most frequently activated oncogenic signalling axis in human cancer, altered in over 70…
Content is based on peer-reviewed scientific literature including data from NCBI, UniProt, PubMed, and TCGA. Gene links reference curated molecular biology databases. For educational purposes only; does not constitute clinical advice.